A Study of the Safety and Efficacy of ONO-7746 in Adult Cancer Patients With Chemotherapy Induced Thrombocytopenia

Ono Pharmaceuticals

Status and phase

Terminated

Phase 1

Conditions

Chemotherapy-Induced Thrombocytopenia

Treatments

Drug: ONO-7746

Study type

Interventional

Funder types

Industry

Identifiers

NCT01345214

ONO-7746POU003

Details and patient eligibility

About

The primary objective of this study is to evaluate the safety and tolerability of ONO-7746 across multiple doses in patients with solid tumors and chemotherapy induced thrombocytopenia (CIT) scheduled to receive at least two cycles of myelosuppressive chemotherapy on Day 1 every 21 days at the same dosages and schedule in the study. The secondary objectives are to characterize the PK profiles of ONO-7746 and to explore the pharmacodynamic effect of ONO-7746 on CIT.

Enrollment

17 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Signed written informed consent
Age ≥ 18 years
Patients with confirmed solid tumor and scheduled to receive at least two cycles of myelosuppressive chemotherapy on Day 1 every 21 days at the same dosage and schedule in the study.
Experienced thrombocytopenia as evidenced by a platelet count < 100 Gi/L in the preceding cycle immediately before study enrollment.
ECOG performance status ≤ 2
For females, surgically sterilized, postmenopausal or agree to use an acceptable form of birth control
Patients treated with novel anticancer agents (e.g. bevacizumab, erlotinib, trastuzumab, cetuximab) may be allowed if it is considered the standard treatment by the investigator and after consultation and approval from the Sponsor
PT/INR and aPTT are within 80% to 120% of the normal range

Exclusion criteria

Experienced thrombocytopenia as evidenced by a platelet count < 25 Gi/L at any time in the preceding cycle immediately before enrollment into the study
History or presence of clinically significant disease
Received any TRAs, or rHuIL-11 within the last 4 weeks prior to screening
Had received a bone marrow or peripheral blood stem cell infusion (within 1 year of screening).
Pregnant, wanting to become pregnant or lactating